Can you take Aldex G with Orforglipron?

The phenylephrine in Aldex G has a moderate potential interaction with Benign Prostatic Hyperplasia.

Sympathomimetic agents may cause or worsen urinary difficulty in patients with prostate enlargement due to smooth muscle contraction in the bladder neck via stimulation of alpha-1 adrenergic receptors. Therapy with sympathomimetic agents should be administered cautiously in patients with hypertrophy or neoplasm of the prostate.

The phenylephrine in Aldex G has a major potential interaction with Cardiovascular Conditions and Disorders.

Sympathomimetic agents may cause adverse cardiovascular effects, particularly when used in high dosages and/or in susceptible patients. In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta- 1 adrenergic receptors. Cardiac output, oxygen consumption, and the work of the heart may be increased. In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors. Palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, coronary occlusion, cerebral vasculitis, myocardial infarction, cardiac arrest, and death have been reported. Some of these agents, particularly ephedra alkaloids (ephedrine, ma huang, phenylpropanolamine), may also predispose patients to hemorrhagic and ischemic stroke. Therapy with sympathomimetic agents should generally be avoided or administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders. These agents should not be used in patients with severe coronary artery disease or severe/uncontrolled hypertension.

The phenylephrine in Aldex G has a major potential interaction with Cerebrovascular Insufficiency.

Sympathomimetic agents may cause adverse cardiovascular effects, particularly when used in high dosages and/or in susceptible patients. In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta- 1 adrenergic receptors. Cardiac output, oxygen consumption, and the work of the heart may be increased. In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors. Palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, coronary occlusion, cerebral vasculitis, myocardial infarction, cardiac arrest, and death have been reported. Some of these agents, particularly ephedra alkaloids (ephedrine, ma huang, phenylpropanolamine), may also predispose patients to hemorrhagic and ischemic stroke. Therapy with sympathomimetic agents should generally be avoided or administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders. These agents should not be used in patients with severe coronary artery disease or severe/uncontrolled hypertension.

Orforglipron has a moderate potential interaction with Dehydration.

There have been reports of acute kidney injury (sometimes requiring hemodialysis) in patients treated with orforglipron. Most events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration (e.g., nausea, vomiting, diarrhea). Renal function should be monitored in patients reporting adverse reactions to orforglipron that may lead to volume depletion, especially when initiating or escalating doses of orforglipron.

The phenylephrine in Aldex G has a moderate potential interaction with Diabetes Mellitus.

Sympathomimetic agents may cause increases in blood glucose concentrations. These effects are usually transient and slight but may be significant with dosages higher than those normally recommended. Therapy with sympathomimetic agents should be administered cautiously in patients with diabetes mellitus. Closer monitoring of blood glucose concentrations may be appropriate.

Orforglipron has a moderate potential interaction with Diabetes Mellitus.

Orforglipron lowers blood glucose and can cause hypoglycemia. In diabetic patients, blood glucose should be monitored before starting and during treatment with orforglipron.

Orforglipron has a moderate potential interaction with Diabetic Retinopathy.

Rapid improvement in glucose control has been associated with a temporary worsening of diabetic retinopathy. Orforglipron has not been studied in patients with diabetic retinopathy and/or macular edema requiring acute treatment. Patients with a history of diabetic retinopathy should be monitored for progression of diabetic retinopathy during treatment with orforglipron.

Orforglipron has a moderate potential interaction with Diarrhea.

There have been reports of acute kidney injury (sometimes requiring hemodialysis) in patients treated with orforglipron. Most events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration (e.g., nausea, vomiting, diarrhea). Renal function should be monitored in patients reporting adverse reactions to orforglipron that may lead to volume depletion, especially when initiating or escalating doses of orforglipron.

Orforglipron has a moderate potential interaction with Gastroparesis.

Use of orforglipron has been associated with gastrointestinal adverse reactions (sometimes severe). Orforglipron is not recommended in patients with severe gastroparesis.

The phenylephrine in Aldex G has a moderate potential interaction with Glaucoma/Intraocular Hypertension.

Sympathomimetic agents can induce transient mydriasis via stimulation of alpha-1 adrenergic receptors. In patients with anatomically narrow angles or narrow-angle glaucoma, pupillary dilation can provoke an acute attack. In patients with other forms of glaucoma, mydriasis may occasionally increase intraocular pressure. Therapy with sympathomimetic agents should be administered cautiously in patients with or predisposed to glaucoma, particularly narrow-angle glaucoma.

The phenylephrine in Aldex G has a major potential interaction with Hyperthyroidism.

Sympathomimetic agents may cause adverse cardiovascular effects, particularly when used in high dosages and/or in susceptible patients. In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta- 1 adrenergic receptors. Cardiac output, oxygen consumption, and the work of the heart may be increased. In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors. Palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, coronary occlusion, cerebral vasculitis, myocardial infarction, cardiac arrest, and death have been reported. Some of these agents, particularly ephedra alkaloids (ephedrine, ma huang, phenylpropanolamine), may also predispose patients to hemorrhagic and ischemic stroke. Therapy with sympathomimetic agents should generally be avoided or administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders. These agents should not be used in patients with severe coronary artery disease or severe/uncontrolled hypertension.

Orforglipron has a moderate potential interaction with Liver Disease.

Orforglipron is not recommended for patients with severe liver dysfunction (Child-Pugh C). No dose adjustment is needed for patients with mild or moderate liver dysfunction (Child-Pugh A or B).

Orforglipron has a major potential interaction with Multiple Endocrine Neoplasia Type II.

Orforglipron is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) and in patients with multiple endocrine neoplasia syndrome type 2. Patients with elevated serum calcitonin or thyroid nodules noted on physical examination or neck imaging should be further evaluated. Patients should be counseled regarding the potential risk for MTC with the use of orforglipron and should be informed of symptoms of thyroid tumors.

The phenylephrine in Aldex G has a major potential interaction with Pheochromocytoma.

Sympathomimetic agents may cause adverse cardiovascular effects, particularly when used in high dosages and/or in susceptible patients. In cardiac tissues, these agents may produce positive chronotropic and inotropic effects via stimulation of beta- 1 adrenergic receptors. Cardiac output, oxygen consumption, and the work of the heart may be increased. In the peripheral vasculature, vasoconstriction may occur via stimulation of alpha-1 adrenergic receptors. Palpitations, tachycardia, arrhythmia, hypertension, reflex bradycardia, coronary occlusion, cerebral vasculitis, myocardial infarction, cardiac arrest, and death have been reported. Some of these agents, particularly ephedra alkaloids (ephedrine, ma huang, phenylpropanolamine), may also predispose patients to hemorrhagic and ischemic stroke. Therapy with sympathomimetic agents should generally be avoided or administered cautiously in patients with sensitivity to sympathomimetic amines, hyperthyroidism, or underlying cardiovascular or cerebrovascular disorders. These agents should not be used in patients with severe coronary artery disease or severe/uncontrolled hypertension.

The phenylephrine in Aldex G has a moderate potential interaction with Prostate Tumor, Benign.

Sympathomimetic agents may cause or worsen urinary difficulty in patients with prostate enlargement due to smooth muscle contraction in the bladder neck via stimulation of alpha-1 adrenergic receptors. Therapy with sympathomimetic agents should be administered cautiously in patients with hypertrophy or neoplasm of the prostate.

Orforglipron has a major potential interaction with Thyroid Tumor.

Orforglipron is contraindicated in patients with a personal or family history of medullary thyroid carcinoma (MTC) and in patients with multiple endocrine neoplasia syndrome type 2. Patients with elevated serum calcitonin or thyroid nodules noted on physical examination or neck imaging should be further evaluated. Patients should be counseled regarding the potential risk for MTC with the use of orforglipron and should be informed of symptoms of thyroid tumors.

Orforglipron has a moderate potential interaction with Vomiting.

There have been reports of acute kidney injury (sometimes requiring hemodialysis) in patients treated with orforglipron. Most events occurred in patients who experienced gastrointestinal adverse reactions leading to dehydration (e.g., nausea, vomiting, diarrhea). Renal function should be monitored in patients reporting adverse reactions to orforglipron that may lead to volume depletion, especially when initiating or escalating doses of orforglipron.